

To whom it may concern

April 20, 2017

**Strategic research collaboration
for discovering novel analgesic drug candidates with Shionogi**

Nissan Chemical Industries, Ltd. (Head Office: Tokyo, Japan; President & CEO: Kojiro Kinoshita; hereinafter called "Nissan Chemical") announced the conclusion of the strategic research collaboration agreement with Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President & CEO: Isao Teshirogi, Ph.D.; hereinafter called "Shionogi") for discovering novel analgesic drug candidates.

This is the 2nd research collaboration program between Nissan Chemical and Shionogi following the program for discovering novel antifungal drug candidates from January 2016. Both two companies will strive to provide best possible analgesic drugs to patients through this collaboration.

About Nissan Chemical Industries, Ltd.

Nissan Chemical Industries, Ltd. is now moving forward to develop new products and businesses through utilization of our core technologies as the chemical company with our corporate vision of becoming "a corporate group that contributes to human survival and development". Nissan Chemical entered into the pharmaceutical business in 1982, and launched an external preparation of ketoprofen, a Ca antagonist and a statin agent with a strong LDL cholesterol reduction. We keep trying research and development for innovative medicines by using precise organic synthesis technology, the strategic chemical library and the state-of-the-art evaluation technology for the smile and precious life around the world.

For more details, please visit <http://www.nissanchem.co.jp/eng/>

Contact information for inquiries on the above

Nissan Chemical Industries, Ltd.
Corporate Planning Department
CSR & Public Relations Office
TEL: +81-3-3296-8320
E-mail: csr_pr@nissanchem.co.jp